Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Different subcellular localizations of ERK2 implicated in breast cancer patient survival
March 2nd, 2006
Researchers suggested different subcellular localizations of ERK2 might be associated with patient survival in breast cancer. "Mitogen-activated protein kinase (MAP kinase) pathways represent a cascade of phosphorylation events, including three pivotal kinases, Raf, MEK and ERK1/2, which have been implicated in the pathogenesis of cancer. We examined 151 cases of invasive breast carcinoma by immunohistochemistry and compared the ERK2 expression with clinicopathological parameters, MMP-11 immunoexpression and patients' survival," scientists in Greece reported. "ERK2 immunoexpression was detected in the cytoplasm and nucleus of cancer cells in 37.7%...
Source: Women's Health Weekly (2006-03-02)
|
